Literature DB >> 31253998

Reduced CTL motility and activity in avascular tumor areas.

Yoav Manaster1, Zohar Shipony1, Anat Hutzler1, Masha Kolesnikov1, Camila Avivi2, Bruria Shalmon2, Iris Barshack2, Michal J Besser3,4, Tali Feferman5, Guy Shakhar6.   

Abstract

Patchy infiltration of tumors by cytotoxic T cells (CTLs) predicts poorer prognosis for cancer patients. The factors limiting intratumoral CTL dissemination, though, are poorly understood. To study CTL dissemination in tumors, we histologically examined human melanoma samples and used mice to image B16-OVA tumors infiltrated by OT-I CTLs using intravital two-photon microscopy. In patients, most CTLs concentrated around peripheral blood vessels, especially in poorly infiltrated tumors. In mice, OT-I CTLs had to cluster around tumor cells to efficiently kill them in a contact-and perforin-dependent manner and cytotoxicity was strictly antigen-specific. OT-I CTLs as well as non-specific CTLs concentrated around peripheral vessels, and cleared the tumor cells around them. This was also the case when CTLs were injected directly into the tumors. CTLs crawled rapidly only in areas within 50 µm of flowing blood vessels and transient occlusion of vessels immediately, though reversibly, stopped their migration. In vitro, oxygen depletion and blockade of oxidative phosphorylation also reduced CTL motility. Taken together, these results suggest that hypoxia limits CTL migration away from blood vessels, providing immune-privileged niches for tumor cells to survive. Normalizing intratumoral vasculature may thus synergize with tumor immunotherapy.

Entities:  

Keywords:  CTLs; Cell motility; Hypoxia; Intravital imaging; Tumor immunotherapy; Tumor vasculature

Mesh:

Substances:

Year:  2019        PMID: 31253998     DOI: 10.1007/s00262-019-02361-5

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  9 in total

1.  Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment.

Authors:  Florence Gazeau; Emmanuel Donnadieu; Alba Nicolas-Boluda; Javier Vaquero; Lene Vimeux; Thomas Guilbert; Sarah Barrin; Chahrazade Kantari-Mimoun; Matteo Ponzo; Gilles Renault; Piotr Deptula; Katarzyna Pogoda; Robert Bucki; Ilaria Cascone; José Courty; Laura Fouassier
Journal:  Elife       Date:  2021-06-09       Impact factor: 8.140

Review 2.  Immune Checkpoint Proteins, Metabolism and Adhesion Molecules: Overlooked Determinants of CAR T-Cell Migration?

Authors:  Luca Simula; Emma Ollivier; Philippe Icard; Emmanuel Donnadieu
Journal:  Cells       Date:  2022-06-06       Impact factor: 7.666

3.  High resolution microfluidic assay and probabilistic modeling reveal cooperation between T cells in tumor killing.

Authors:  Gustave Ronteix; Shreyansh Jain; Christelle Angely; Marine Cazaux; Roxana Khazen; Philippe Bousso; Charles N Baroud
Journal:  Nat Commun       Date:  2022-06-03       Impact factor: 17.694

Review 4.  Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.

Authors:  Emmanuel Donnadieu; Loïc Dupré; Lia Gonçalves Pinho; Vinicius Cotta-de-Almeida
Journal:  J Leukoc Biol       Date:  2020-07-03       Impact factor: 4.962

Review 5.  Hypoxia and Extracellular Acidification as Drivers of Melanoma Progression and Drug Resistance.

Authors:  Ewelina Dratkiewicz; Aleksandra Simiczyjew; Justyna Mazurkiewicz; Marcin Ziętek; Rafał Matkowski; Dorota Nowak
Journal:  Cells       Date:  2021-04-09       Impact factor: 6.600

Review 6.  Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy.

Authors:  Evelien A J van Genugten; Jetty A M Weijers; Sandra Heskamp; Manfred Kneilling; Michel M van den Heuvel; Berber Piet; Johan Bussink; Lizza E L Hendriks; Erik H J G Aarntzen
Journal:  Front Oncol       Date:  2022-01-07       Impact factor: 6.244

7.  Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer.

Authors:  Ming Chen; Runzhe Chen; Ying Jin; Jun Li; Xin Hu; Jiexin Zhang; Junya Fujimoto; Shawna M Hubert; Carl M Gay; Bo Zhu; Yanhua Tian; Nicholas McGranahan; Won-Chul Lee; Julie George; Xiao Hu; Yamei Chen; Meijuan Wu; Carmen Behrens; Chi-Wan Chow; Hoa H N Pham; Junya Fukuoka; Jia Wu; Edwin Roger Parra; Latasha D Little; Curtis Gumbs; Xingzhi Song; Chang-Jiun Wu; Lixia Diao; Qi Wang; Robert Cardnell; Jianhua Zhang; Jing Wang; Xiuning Le; Don L Gibbons; John V Heymach; J Jack Lee; William N William; Chao Cheng; Bonnie Glisson; Ignacio Wistuba; P Andrew Futreal; Roman K Thomas; Alexandre Reuben; Lauren A Byers; Jianjun Zhang
Journal:  Nat Commun       Date:  2021-11-17       Impact factor: 17.694

Review 8.  When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy.

Authors:  Linna Yu; Yi Jin; Mingjie Song; Yu Zhao; Huaqing Zhang
Journal:  Pharmaceutics       Date:  2022-07-30       Impact factor: 6.525

Review 9.  Therapeutic targeting of the hypoxic tumour microenvironment.

Authors:  Dean C Singleton; Andrew Macann; William R Wilson
Journal:  Nat Rev Clin Oncol       Date:  2021-07-29       Impact factor: 66.675

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.